- Home
- MERC vs IXHL Comparison
MERC vs IXHL Comparison
Compare MERC & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MERC | IXHL |
|---|---|---|
| Founded | 1968 | 2001 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 97.6M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MERC | IXHL |
|---|---|---|
| Price | $1.79 | $4.19 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 775.4K | ★ 6.5M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | $12,000.00 |
| Revenue This Year | $13.59 | N/A |
| Revenue Next Year | $10.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $1.48 | $0.11 |
| 52 Week High | $7.98 | $1.66 |
Technical Indicators
Market Signals| Indicator | MERC | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 96.09 |
| Support Level | $1.54 | $0.32 |
| Resistance Level | $2.25 | N/A |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 36.09 | 80.26 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.